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Abstract
Background: This study was carried out to determine the effects of vitamin D and omega-3 fatty acids co-
supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes
(GDM) patients.
Methods: This randomized, double-blind, placebo-controlled trial was conducted among 120 GDM women. Participants
were randomly divided into four groups to receive: 1) 1000 mg omega-3 fatty acids containing 180 mg eicosapentaenoic
acid (EPA) and 120 mg docosahexaenoic acid (DHA) twice a day + vitamin D placebo (n = 30); 2) 50,000 IU vitamin D
every 2 weeks + omega-3 fatty acids placebo (n = 30); 3) 50,000 IU vitamin D every 2 weeks + 1000 mg omega-3 fatty
acids twice a day (n = 30) and 4) vitamin D placebo + omega-3 fatty acids placebo (n = 30) for 6 weeks.
Results: Subjects who received vitamin D plus omega-3 fatty acids supplements compared with vitamin D, omega-3
fatty acids and placebo had significantly decreased high-sensitivity C-reactive protein (−2.0 ± 3.3 vs. -0.8 ± 4.4, −1.3 ± 2.4
and +0.9 ± 2.7 mg/L, respectively, P = 0.008), malondialdehyde (−0.5 ± 0.5 vs. −0.2 ± 0.5, −0.3 ± 0.9 and +0.5 ± 1.4 μmol/L,
respectively, P < 0.001), and increased total antioxidant capacity (+92.1 ± 70.1 vs. +55.1 ± 123.6, +88.4 ± 95.2 and +1.0 ± 90.
8 mmol/L, respectively, P = 0.001) and glutathione (+95.7 ± 86.7 vs. +23.0 ± 62.3, +30.0 ± 66.5 and −7.8 ± 126.5 μmol/L,
respectively, P = 0.001). In addition, vitamin D and omega-3 fatty acids co-supplementation, compared with vitamin D,
omega-3 fatty acids and placebo, resulted in lower incidences of newborns’ hyperbilirubinemiain (P = 0.037) and
newborns’ hospitalization (P = 0.037).
Conclusion: Overall, vitamin D and omega-3 fatty acids co-supplementation for 6 weeks among GDM women had
beneficial effects on some biomarkers of inflammation, oxidative stress and pregnancy outcomes.
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Background
Gestational diabetes mellitus (GDM) is impaired glucose
tolerance and insulin resistance with first onset during
pregnancy [1]. It affect approximately 5% of all pregnan-
cies worldwide [2]. The its prevalence in US [3] and Iran
[4] was reported 5.8 and 4.7%, respectively. GDM is as-
sociated with serious maternal and fetal complications
including pre-eclampsia, fetal macrosomia, shoulder
dystocia, neonatal hypoglycemia and maternal complica-
tions [5]. In addition, a 7-fold increased risk for develop-
ing type 2 diabetes mellitus (T2DM) was reported in
GDM women [6]. Increased inflammatory factors con-
tribute to pregnancy-induced insulin resistance and the
development of glucose intolerance [7]. Hyperglycemia
in GDM increases oxidative stress through several mo-
lecular mechanisms including the activation of protein
kinase C and increased reactive oxygen species produc-
tion in mitochondria [8].
Previous studies have reported that vitamin D [9] and
omega-3 fatty acids levels [10] were low in GDM
patients than those healthy pregnant women. Earlier, the
beneficial effects of single supplementation with vitamin
D or omega-3 fatty acids on biomarkers of inflammation,
oxidative stress and pregnancy outcomes in GDM
women were reported [11, 12]. We are aware of no study
that examined the effect of vitamin D or omega-3 fatty
acids co-supplementation on inflammatory factors, bio-
markers of oxidative stress and pregnancy outcomes in
GDM. Nowadays, there is a growing interest to use vita-
min D and omega-3 fatty acids during pregnancy espe-
cially in GDM women. In a study by Mojibian et al. [13],
it was observed that supplementation with 50,000 IU
vitamin D every 2 weeks to women with gestational age
12–16 weeks until delivery decreased the incidence of
GDM, but did not affect the incidence of pre-eclampsia,
gestational hypertension, preterm labor, and low birth
weight. Furthermore, in a meta-analysis study, omega-
3 fatty acids supplementation during pregnancy was
associated with the reduced risk of preterm delivery
and improved size of the newborn [14]. However,
docosahexaenoic acid (DHA) supplementation of
800 mg/day in the second half of pregnancy could
not reduce the risk of GDM or pre-eclampsia [15].
There are speculations that vitamin D and omega-3
fatty acids may improve biomarkers of inflammation and
oxidative stress, and pregnancy outcomes due to their
effects on maternal metabolic profiles [16], increased
metabolism of bile acids [17] and inhibiting the
activation of nuclear factor-κB (NF-кB) [18]. This
study was, therefore, carried out to determine the
effects of vitamin D and omega-3 fatty acids co-
supplementation on biomarkers of inflammation
(primary outcomes), oxidative stress and pregnancy
outcomes (secondary outcomes) in GDM women.
Methods
Trial design and participants
The present study, registered in the Iranian website for
registration of clinical trials (http://www.irct.ir: IRCT20
1701305623N106), was a 6-week randomized double-
blind placebo controlled clinical trial that was carried
out among 120 GDM women at 24–28 weeks’ gestation,
aged 18–40 years without prior diabetes diagnosed based
on the American Diabetes Association guidelines [19]
from September 2016 to March 2017. This study was
approved by the research ethics committee of Ardabil
University of Medical Sciences (AUMS) and written
informed consent was taken from all patients. Exclusion
criteria were taking omega-3 fatty acids supplements,
insulin therapy, placenta abruption, pre-eclampsia,
eclampsia, hypo and hyperthyroidism, and smokers.
Study design
At first, participants were randomly assigned into four
groups to take either 1000 mg omega-3 fatty acids con-
taining 180 mg eicosapentaenoic acid (EPA) and 120 mg
DHA twice a day + vitamin D placebo (n = 30) or
50,000 IU vitamin D every 2 weeks + omega-3 fatty acids
placebo (n = 30) or 50,000 IU vitamin D every 2 weeks +
1000 mg omega-3 fatty acids twice a day (n = 30) or vita-
min D and omega-3 fatty acids placebos (n = 30) for
6 weeks. Although, the duration of intervention was
6 weeks, all participants were followed up until the de-
livery. The placebo capsule contained 500 mg of liquid
paraffin. Due to lack of evidence about the appropriate
dosage of vitamin D and omega-3 fatty acids for patients
with GDM, we used the above-mentioned dose of vita-
min D based on a previous study in GDM women [20]
and dose of omega-3 fatty acids based on a previous
study in patients with end-stage renal disease [21]. The
appearance of the placebo capsule was indistinguishable
in color, shape, size, and packaging, smell and taste from
vitamin D and omega-3 fatty acids capsules. Vitamin D
and omega-3 fatty acids capsules were produced by
Zahravi Pharmaceutical Company, Tabriz, Iran, that ap-
proved by Food and Drug Administration. Compliance
with the consumption of supplements and placebos was
assessed by examining the tablet containers as well as by
the measurement of serum 25-hydroxyvitamin D con-
centrations with the enzyme-linked immunosorbent
assay (ELISA) method. To increase compliance, all
participants received short messages on their cell phones
every day to remind them about taking the capsules.
Randomization assignment was conducted using computer-
generated random numbers. Randomization and allocation
were concealed from the researchers and participants until
the final analyses were completed. Another person, who was
not involved in the trial and not aware of random sequences,
assigned the subjects to the numbered bottles of capsules.
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Subjects were requested not to change their routine physical
activity or usual dietary intakes throughout the study and not
to consume any supplements other than the one provided to
them by the investigators as well as not to take any medica-
tions that might affect findings during the 6-wk intervention.
Dietary macro- and micro-nutrients intakes were determined
using the 3-day food records at weeks 0, 3, 5 and 6 of the
intervention. Modified Nutritionist-4 software program (First
Databank, San Bruno, CA) was used to determine macro-
and micro-nutrients intakes. Physical activity was described
as metabolic equivalents (METs) in hours per day [22].
Assessment of anthropometric measurements
Weight and height (Seca, Hamburg, Germany) were deter-
mined at baseline and after the treatment in a fasting sta-
tus without shoes and a minimal clothing state by trained
staff. BMI was calculated using the height and weight
measurements (weight in kg/ [height in meters] 2).
Outcomes
In the current study, the primary outcomes measure-
ments were inflammatory factors. The secondary out-
comes measurements were biomarkers of oxidative
stress and pregnancy outcomes.
The measured outcomes of GDM women were bio-
markers of inflammation and oxidative, cesarean section,
preterm delivery, pre-eclampsia, polyhydramnios and
gestational age. The measured outcomes of newborns
were macrosomia, newborns’ weight, length and head
circumference, apgar score, and newborns’ hyperbilirubi-
nemia, hospitalization and hypoglycemia.
Assessment of biochemical variables
Five milliliter fasting blood samples were obtained from
each patient at the AUMS reference laboratory, Ardabil,
Iran, at baseline and the end of the study. Blood samples
was collected in 2 separate tubes: 1) one without EDTA
to separate the serum, in order to evaluate serum 25-
hydroxyvitamin D and high sensitivity C-reactive protein (hs-
CRP) concentrations and 2) another one containing EDTA to
examine plasma nitric oxide (NO), total antioxidant capacity
(TAC), total glutathione (GSH) and malondialdehyde (MDA).
Blood samples were immediately centrifuged (Hettich D-
78532, Tuttlingen, Germany) at 3500 rpm for 10 min to sep-
arate the serum. Serum 25-hydroxyvitamin D concentrations
were assessed by an ELISA kit (IDS, Boldon, UK) with inter-
and intra-assay coefficient variances (CVs) of 4.4 to 6.6%,
respectively. Serum hs-CRP levels were quantified using an
ELISA kit (LDN, Nordhorn, Germany) with intra- and inter-
assay CVs of 3.4 and 5.1%, respectively. The plasma NO levels
by Griess method [23], TAC concentrations using the ferric
reducing antioxidant power method developed by Benzie and
Strain [24], GSH by the method of Beutler et al. [25] and
MDA levels by the thiobarbituric acid reactive substance
spectrophotometric test [26] were determined. CVs for
plasma NO, TAC, GSH and MDA were lower than 5%.
Newborns’ hyperbilirubinemia was considered when
the total serum bilirubin levels were at or above 15 mg/
dL (257 mol/L) in infants 25 to 48 h old, 18 mg/dL
(308 mol/L) in infants 49 to 72 h old, and 20 mg/dL
(342 mol/L) in infants older than 72 h [27].
Clinical assessment
Polyhydramnios was diagnosed using the sonographic
estimation method at post-intervention. On the basis of
this measurement, polyhydramnios was defined as an
amniotic fluid index (AFI) in excess of 25 cm [16]. Pre-
term delivery was defined as delivery occurred at
<37 weeks of pregnancy and newborn’s macrosomia was
defined as birth weight of >4000 g.
Statistical methods
To calculate the sample size, we used the standard for-
mula suggested for clinical trials by considering type one
error (α) of 0.05 and type two error (β) of 0.20 (power =
80%). Based on a previous study [12], we used
1570.5 ng/mL as SD and 1250.0 ng/mL as the difference
in mean (d) of hs-CRP concentrations as primary vari-
able. Based on this, we needed 25 patients in each group.
Considering a dropouts of 5 patients per group, we cal-
culated to have 30 patients per group.
The Kolmogrov-Smirnov test was used to establish the
normal distribution of variables. One-way analysis of variance
(ANOVA) was used to detect differences in general charac-
teristics and dietary intakes between the four groups. The
changes across three groups were compared using Bonferoni
post hoc pair-wise comparisons. The Pearson Chi-square test
was used to compare categorical variables. To determine the
effects of vitamin D plus omega-3 fatty acids supplementa-
tion on biomarkers of inflammation and oxidative stress, we
used ANOVA. To assess if the magnitude of the change
depended on the baseline values, we adjusted all analyses for
the baseline values, age and baseline BMI to avoid the poten-
tial bias that might have resulted with ANCOVA test. P-
values <0.05 were considered statistically significant. All
statistical analyses were done using the Statistical Package for
Social Science version 17 (SPSS Inc., Chicago, Illinois, USA).
Results
Initially, 130 subjects were screened; of whom 10 sub-
jects were excluded due to not living in Ardabil (n = 5)
and not meeting inclusion criteria. In the current study,
120 GDM women [vitamin D (n = 30), omega-3 fatty
acids (n = 30), vitamin D plus omega-3 fatty acids (n =
30) and placebo (n = 30)] completed the trial (Fig. 1). On
average, the rate of compliance in the present study was
high, such that higher than 90% of capsules were taken
throughout the study in both groups. No side effects
Razavi et al. Nutrition & Metabolism  (2017) 14:80 Page 3 of 9
were reported following the supplementation of vitamin
D and omega-3 fatty acids supplements in women with
GDM throughout the study.
Mean age and height of study participants were not
statistically different between the four groups
(Table 1). Baseline weight and BMI as well as their
means after intervention were not significant different
comparing the groups.
Based on the 3-day dietary records obtained through-
out the intervention, no statistically significant change
was seen between the four groups in terms of dietary in-
takes of macro- and micronutrients (Data not shown).
After 6 weeks of intervention, co-supplementation
with vitamin D and omega-3 fatty acids led to a signifi-
cant increase in serum 25-hydroxyvitamin D values
(+19.5 ± 3.2 vs. +18.1 ± 4.4, +0.7 ± 2.8 and −0.2 ± 1.7 ng/mL,
respectively, P < 0.001) compared with vitamin D, omega-3
fatty acids and placebo (Table 2). In addition, subjects who
received vitamin D plus omega-3 fatty acids supplements
compared with vitamin D, omega-3 fatty acids and placebo
Fig. 1 Summary of patient flow diagram, 1 Individuals received 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fatty acids twice a
day, 2 Individuals received 1000 mg omega-3 fatty acids (180 mg EPA and 120 mg DHA) twice a day plus placebo for vitamin D every 2 weeks, 3
Individuals received 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatty acids twice a day
Table 1 General characteristics of study participants1
Placebo
(n = 30)
Vitamin D 2
(n = 30)
Omega-33
(n = 30)
Vitamin D+ omega-34
(n = 30)
P5
Age (y) 29.2 ± 3.4 29.9 ± 5.0 29.7 ± 3.6 29.9 ± 4.0 0.869
Height (cm) 161.6 ± 4.8 161.5 ± 4.1 161.5 ± 3.4 161.8 ± 3.7 0.985
Weight at study baseline (kg) 75.1 ± 7.7 76.1 ± 12.7 74.3 ± 5.8 77.4 ± 10.2 0.632
Weight at end-of-trial (kg) 77.5 ± 7.7 78.6 ± 12.5 76.7 ± 6.1 80.0 ± 10.0 0.559
Weight change (kg) 2.3 ± 0.7 2.5 ± 1.1 2.4 ± 0.5 2.6 ± 0.6 0.570
BMI at study baseline (kg/m2) 28.8 ± 3.4 29.2 ± 5.0 28.5 ± 2.4 29.5 ± 3.8 0.746
BMI at end-of-trial (kg/m2) 29.7 ± 3.4 30.1 ± 4.8 29.4 ± 2.5 30.5 ± 3.7 0.683
BMI change (kg/m2) 0.9 ± 0.3 1.0 ± 0.4 0.9 ± 0.2 1.0 ± 0.2 0.592
1Data are means ± SDs
2Receiving 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fatty acids twice a day
3Receiving 1000 mg omega-3 fatty acids (180 mg EPA and 120 mg DHA) twice a day plus placebo for vitamin D every 2 weeks
4Receiving 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatty acids twice a day
5Obtained from ANOVA test
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had significantly decreased serum hs-CRP (−2.0 ± 3.3 vs.
−0.8 ± 4.4, −1.3 ± 2.4 and +0.9 ± 2.7 mg/L, respectively, P=
0.008), plasma MDA (−0.5 ± 0.5 vs. -0.2 ± 0.5, −0.3 ± 0.9 and
+0.5 ± 1.4 μmol/L, respectively, P < 0.001), and increased
plasma TAC (+92.1 ± 70.1 vs. +55.1 ± 123.6, +88.4 ± 95.2 and
+1.0 ± 90.8 mmol/L, respectively, P= 0.001) and GSH levels
(+95.7 ± 86.7 vs. +23.0 ± 62.3, +30.0 ± 66.5 and −7.8 ±
126.5 μmol/L, respectively, P = 0.001). Co-supplementation
with vitamin D and omega-3 fatty acids had no significant ef-
fect on plasma NO levels.
There was a significant difference in baseline levels
of plasma NO (P < 0.001), TAC (P < 0.001), GSH (P =
0.02) and MDA (P < 0.001) between the four groups.
When we adjusted the analysis for baseline values of
biochemical parameters, age and baseline BMI,
findings did not change except plasma NO levels
(0.020) (Table 3).
Vitamin D and omega-3 fatty acids co-supplementation,
compared with vitamin D, omega-3 fatty acids and
placebo, resulted in lower incidences of newborns’ hyper-
bilirubinemiain (10.0% vs. 20.0%, 33.3% and 40.0%, re-
spectively, P = 0.037) and newborns’ hospitalization (10.0%
vs. 20.0%, 33.3% and 40.0%, respectively, P = 0.037), but
did not affect other pregnancy outcomes (Table 4).
Discussion
To our knowledge, this study is the first report of the effects
of vitamin D and omega-3 fatty acids co-supplementation
on biomarkers of inflammation, oxidative stress and preg-
nancy outcomes among women with GDM. We found that
Table 2 The effect of vitamin D plus omega-3 fatty acids supplementations on biomarkers of inflammation and oxidative in
gestational diabetes patients1
Placebo
(n = 30)
Vitamin D2
(n = 30)
Omega-33
(n = 30)
Vitamin D+ omega-34
(n = 30)
P5
Serum 25-OH-vitamin D (ng/mL)
Baseline 14.9 ± 3.2 13.6 ± 3.7 15.6 ± 4.0 14.2 ± 2.9 0.156
End 14.7 ± 3.2 31.7 ± 6.8 16.3 ± 4.6 33.8 ± 4.6 <0.001
Change -0.2 ± 1.7 18.1 ± 4.4b 0.7 ± 2.8 19.5 ± 3.2b <0.001
hs-CRP (mg/L)
Baseline 7.2 ± 3.9 7.2 ± 6.4 8.0 ± 6.2 8.3 ± 4.6 0.815
End 8.1 ± 4.0 6.4 ± 3.9 6.7 ± 5.9 6.3 ± 4.7 0.407
Change 0.9 ± 2.7 -0.8 ± 4.4 −1.3 ± 2.4 −2.0 ± 3.3a 0.008
NO (μmol/L)
Baseline 51.1 ± 13.0 54.1 ± 4.9 46.9 ± 4.9 46.1 ± 5.2 <0.001
End 52.5 ± 15.4 60.0 ± 7.9 51.5 ± 7.3 48.4 ± 5.1 <0.001
Change 1.4 ± 11.4 5.9 ± 9.0 4.6 ± 9.2 2.3 ± 7.5 0.230
TAC (mmol/L)
Baseline 748.1 ± 109.7 807.2 ± 96.6 811.0 ± 54.3 906.4 ± 73.9 <0.001
End 749.1 ± 91.2 862.3 ± 91.9 899.4 ± 112.8 998.5 ± 82.1 <0.001
Change 1.0 ± 90.8 55.1 ± 123.6 88.4 ± 95.2a 92.1 ± 70.1a 0.001
GSH (μmol/L)
Baseline 491.8 ± 173.5 456.6 ± 67.8 532.5 ± 49.6 518.3 ± 64.2 0.020
End 484.0 ± 161.2 479.6 ± 59.7 562.5 ± 57.8 594.2 ± 60.9 <0.001
Change −7.8 ± 126.5 23.0 ± 62.3 30.0 ± 66.5 75.9 ± 86.7a 0.005
MDA (μmol/L)
Baseline 3.2 ± 1.0 2.7 ± 0.4 3.5 ± 0.8 3.0 ± 0.5 <0.001
End 3.7 ± 1.6 2.5 ± 0.3 3.2 ± 0.4 2.5 ± 0.3 <0.001
Change 0.5 ± 1.4 −0.2 ± 0.5a −0.3 ± 0.9a −0.5 ± 0.5a <0.001
1Data are means ± SDs
2Receiving 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fatty acids twice a day
3Receiving 1000 mg omega-3 fatty acids (180 mg EPA and 120 mg DHA) twice a day plus placebo for vitamin D every 2 weeks
4Receiving 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatty acids twice a day
5Obtained from ANOVA test
GSH, glutathione; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; TAC, total antioxidant capacity
aSignificant difference with the placebo group
bSignificant difference with the placebo and omega-3 fatty acids groups
Razavi et al. Nutrition & Metabolism  (2017) 14:80 Page 5 of 9
vitamin D and omega-3 fatty acids co-supplementation for
6 weeks to GDM women had beneficial effects on maternal
serum hs-CRP, plasma TAC, GSH, MDA levels, and new-
borns’ hyperbilirubinemiain and hospitalization, but did not
influence plasma NO levels and other pregnancy outcomes.
In the current study, we hypothesized that combined ther-
apy with vitamin D and omega-3 fatty acids in GDM
women may work better than a single supplementa-
tion alone. In addition, vitamin D and omega-3 fatty
acids co-supplementation might have a strong syner-
gistic effect on biomarkers of inflammation, oxidative
stress and pregnancy outcomes. In a study by Baidal
et al. [28], it was observed that combined omega-3
fatty acids and vitamin D3 therapy was well tolerated
and had beneficial effects on beta-cell function in pa-
tients with onset type 1 diabetes. Gurol et al. [29]
also demonstrated that omega-3 fatty acids and vita-
min D had a synergistic effect on glycemia in islet
transplantation. Furthermore, omega-3 fatty acids sup-
plementation may result in increased circulating levels
of vitamin D. In a study by An et al. [30], it was seen
that 1,25(OH)2D levels significantly increased in dialy-
sis patients compared to baseline after 3 months of
omega-3 fatty acids supplementation without vitamin
D. Omega-3 fatty acids intake may also overcome the
inverse association of vitamin D deficiency with
Table 3 Adjusted changes in metabolic variables in gestational diabetes patients that received either vitamin D plus omega-3 fatty
acids, omega-3 fatty acids and vitamin D supplements or placebo1
Placebo
(n = 30)
Vitamin D 2
(n = 30)
Omega-33
(n = 30)
Vitamin D+ omega-34
(n = 30)
P5
Serum 25-OH-vitamin D (ng/mL) −0.2 ± 0.6 18.2 ± 0.6 0.7 ± 0.6 19.5 ± 0.6 <0.001
hs-CRP (mg/L) 0.8 ± 0.5 −1.0 ± 0.5 −1.2 ± 0.5 −1.9 ± 0.5 0.004
NO (μmol/L) 1.9 ± 1.6 7.9 ± 1.6 3.3 ± 1.6 1.0 ± 1.6 0.020
TAC (mmol/L) −35.5 ± 17.1 49.1 ± 15.9 85.5 ± 15.8 137.6 ± 17.8 <0.001
GSH (μmol/L) −12.4 ± 14.2 5.6 ± 14.5 45.2 ± 14.4 83.8 ± 14.3 <0.001
MDA (μmol/L) 0.5 ± 0.1 −0.4 ± 0.2 −0.1 ± 0.2 −0.5 ± 0.1 <0.001
1All values are means ± SEs. Values are adjusted for baseline values of parameters of biochemical, age and baseline BMI
2Receiving 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fatty acids twice a day
3Receiving 1000 mg omega-3 fatty acids (180 mg EPA and 120 mg DHA) twice a day plus placebo for vitamin D every 2 weeks
4Receiving 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatty acids twice a day
5Obtained from ANCOVA test
GSH, glutathione; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; TAC, total antioxidant capacity
Table 4 The association of vitamin D plus omega-3 fatty acids supplementation with pregnancy outcomes
Placebo group
(n = 30)
Vitamin D 2
(n = 30)
Omega-33
(n = 30)
Vitamin D+ omega-34
(n = 30)
P5
Cesarean section (%) 11 (36.7) 9 (30.0) 9 (30.0) 8 (26.7) 0.863†
Preterm delivery (%) 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 0.388†
Pre-eclampsia (%) 3 (10.0) 3 (10.0) 2 (6.7) 3 (10.0) 0.960†
Polyhydramnios (%) 2 (6.6) 2 (6.6) 2 (6.6) 2 (6.6) >0.999†
Macrosomia > 4000 g (%) 5 (16.7) 2 (6.7) 3 (10.0) 2 (6.7) 0.525†
Gestational age (weeks) 39.1 ± 1.1 39.2 ± 1.0 39.0 ± 1.4 39.3 ± 0.9 0.658
Newborns’ weight (g) 3323.0 ± 407.1 3308.3 ± 604.0 3475.0 ± 395.2 3311.7 ± 502.2 0.480
Newborns’ length (cm) 50.4 ± 1.1 50.2 ± 3.0 51.3 ± 2.1 49.9 ± 2.7 0.103
Newborns’ head circumference (cm) 35.7 ± 1.3 35.9 ± 2.9 35.5 ± 1.4 35.3 ± 2.7 0.744
1- min Apgar score 8.8 ± 0.4 8.7 ± 0.4 8.7 ± 0.4 8.8 ± 0.4 0.779
5- min Apgar score 9.8 ± 0.4 9.7 ± 0.4 9.7 ± 0.4 9.8 ± 0.4 0.779
Newborns’ hyperbilirubinemia (%) 12 (40.0) 6 (20.0) 10 (33.3) 3 (10.0) 0.037†
Newborns’ hospitalization (%) 12 (40.0) 6 (20.0) 10 (33.3) 3 (10.0) 0.037†
Newborns’ hypoglycemia (%) 6 (20.0) 4 (13.3) 5 (16.7) 4 (13.3) 0.876†
Values are means ± SDs for continuous measures and are number (%) for dichotomous variables
†Obtained from Pearson Chi-square test
2Receiving 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fatty acids twice a day
3Receiving 1000 mg omega-3 fatty acids (180 mg EPA and 120 mg DHA) twice a day plus placebo for vitamin D every 2 weeks
4Receiving 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatty acids twice a day
5Obtained from ANOVA test
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inflammation [31]. As most patients of our study had
vitamin D deficiency, decreased inflammatory markers
may improve pregnancy outcomes.
The current study showed that vitamin D and omega-
3 fatty acids co-supplementation to GDM women for
6 weeks resulted in a significant reduction in serum hs-
CRP, but did not affect plasma NO levels compared with
other groups. Although few studies have assessed benefi-
cial effects of vitamin D or omega-3 fatty acids supple-
mentation on inflammatory cytokines, to the best of our
knowledge, data on the effects of vitamin D and omega-
3 fatty acids co-supplementation on inflammatory cyto-
kines are scarce. We have previously demonstrated that
supplementation with 50,000 IU of vitamin D every
3 weeks [11] or 1000 mg/day of omega-3 fatty acids [12]
for 6 weeks to GDM women had beneficial effects on
few pregnancy outcomes. Likewise, in some studies,
vitamin D supplementation in patients with a history of
myocardial infarction and elderly women with vitamin D
deficiency was associated with a significant reduction in
circulating levels of CRP [32, 33]. The administration of
fish oil at a dosage of 3 g/day to men with coronary ar-
tery disease for 8 weeks decreased hs-CRP levels [34].
However, in GDM women, vitamin D supplementation
at a dosage of 50,000 IU every 2 weeks for 2 months had
no significant effect on hs-CRP levels [20]. In addition,
short-term omega-3 fatty acids supplementation (3 g/day
for 8 weeks) in patients with T2DM could not affect
CRP levels [35]. Increasing production of inflammatory
cytokines in GDM would result in increased adiposity at
birth [36] as well as predisposes the newborn to become
overweight and develop metabolic diseases including
glucose intolerance, metabolic syndrome, and cardiovas-
cular disease [37, 38]. Less production of parathyroid
hormone after vitamin D intake [39] might result in the
reducing production of inflammatory factors including
CRP. Furthermore, increased gene expression of peroxi-
some proliferator-activated receptors by omega-3
inhibits the activation of NF-кB [18], which in turn can
decrease the production of inflammatory cytokines.
We demonstrated that vitamin D plus omega-3 fatty
acids supplementation in GDM women for 6 weeks led to
significant increases in plasma TAC and GSH concentra-
tions, and a significant decrease in plasma MDA levels
compared with other groups. Similarly our findings were
observed following high-dose vitamin D supplementation
(50,000 IU every 2 weeks) increased TAC and GSH
concentrations in patients with GDM [40]. In addition,
supplementation with vitamin D at a dosage of 200,000 IU
significantly increased TAC levels in elderly subjects with
vitamin D insufficiency [33]. Vitamin D supplementation
at a dosage of 100,000 IU monthly for 3 months to over-
weight and obese subjects also decreased oxidative stress
mediators of arterial stiffness [41]. On the other hand, a
significant beneficial effect was seen following supplemen-
tation with 400 mg/day of DHA for 2 weeks on platelet
function and oxidative stress in patients with T2DM [42].
Furthermore, fish oil supplementation significantly de-
creased biomarkers of oxidative stress after a single bout
of eccentric exercise in healthy man [43]. However,
supplementation of fish oil to patients with Alzheimer’s
disease for 6 months did not affect biomarkers of oxida-
tive stress [44]. Oxidative stress imbalance in GDM is
important in the pathophysiological processes involved in
vascular diseases, such as diabetes, hypertension and
cardiovascular diseases [45]. Vitamin D intake can im-
prove oxidative stress through its antioxidant properties
[46], and decreasing production of reactive oxygen species
and pro-inflammatory cytokines [47]. In addition, ob-
served beneficial effects on biomarkers of oxidative stress
by omega-3 fatty acids may be mediated by their anti-
inflammatory properties [48].
It must be kept in mind that in the current study, vita-
min D and omga-3 fatty acids co-supplementation may
have an indirect role in newborns’ hyperbilirubinemia and
hospitalization due to their effects on improved bio-
markers of inflammation and oxidative stress. In a study
by Kalra et al. [49], it observed that supplementation with
one dose of 1500 μg vitamin D3 in the second trimester
or two doses of 3000 μg vitamin D3 each in the second
and third trimesters resulted in improved liver enzyme
levels in cord blood of the infants. In addition, fish oil sup-
plementation (0.2 g/kg body weight daily) for 5 days in
postoperative cancer subjects was associated with signifi-
cant reductions of bilirubin and liver enzymes levels [50].
However, supplementation with 25 mg/day of ergocalcif-
erol to pregnant women did not affect mean birth weight
[51, 52]. Moreover, supplementation with 600 mg/day of
DHA in the last half of gestation resulted in overall greater
gestation duration and infant size [53]. Active form of
vitamin D induces vitamin D receptors, which in turn act
as a receptor for secondary bile acids, such as lithocholic
acid and 3-ketocholanic acid, and leads to their catabolism
via induction of cytochrome 3A enzymes [17, 54].
Few limitations must be considered in the interpretation
of our findings. The main limitation of our study is the
lack of measurements of circulating levels of EPA, DHA
and other omega-3 fatty acids at baseline and after the 6-
week intervention due to budget limitations. In addition,
further studies are needed to assess the gene expression
related to inflammation and oxidative stress to explore the
plausible mechanism and confirm our findings.
Conclusions
Overall, vitamin D and omega-3 fatty acids co-
supplementation for 6 weeks among GDM women had
beneficial effects on some biomarkers of inflammation,
oxidative stress and pregnancy outcomes.
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